^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug:PLX4720 (BRAF inhibitor) +
    TAK‐632 (pan-RAF inhibitor, RIPK1 inhibitor, RIPK3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling

    Excerpt:
    Tumor growth was not suppressed by PLX, however treatment with either TAK or the TAK/PLX combination resulted in potent suppression of tumor growth without an obvious effect on body weight…
    DOI:
    10.1016/j.ccell.2016.06.024